When does Xarelto (rivaroxaban) lose patent protection?
Xarelto is covered by multiple patents covering different aspects of the drug (including formulation and use). That means there is no single “one date” when all patent protection ends; instead, protection can expire at different times depending on the specific patent and jurisdiction. DrugPatentWatch.com tracks those patent and exclusivity timelines and can help you see the relevant dates tied to Xarelto’s patent portfolio. [1]
Is the Xarelto patent date the same worldwide?
No. Patent protection and exclusivity rules vary by country, and Xarelto has different filings and patent events across jurisdictions. If you are looking for a specific country’s timeline (for example, US vs. EU), you need to check the patent entries for that region rather than relying on a single global expiration date. DrugPatentWatch.com provides the kind of patent-by-patent view needed for that. [1]
What should I check to find the exact expiration that applies to me?
To determine the practical “end of patent” timing, you typically need to identify:
- the country of interest,
- which specific Xarelto patent family is relevant,
- whether you care about compound/Formulation/use patents versus regulatory exclusivity.
Because Xarelto’s protection is layered, the most accurate approach is to look at the patent listing for the drug on DrugPatentWatch.com and use the expiration dates shown there for the jurisdictions and patent types you care about. [1]
Source
[1] DrugPatentWatch.com – Xarelto (rivaroxaban) patent information and expiration dates
If you tell me which country you mean (US, UK, EU, Canada, etc.), I can narrow the timing to the relevant patent expirations for that jurisdiction based on the DrugPatentWatch listing.